EICHOR
● Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Condition: Solid Tumors · Hematologic Malignancies · Sponsor: Merck Sharp & Dohme LLC
About this study
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W …
This description comes directly from the study's public registry record.
Talk to the study team
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
Locations (780)
| Arizona Cancer Center at UMC North ( Site 0018) | Tucson, Arizona, United States | Recruiting |
| Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 0054) | Bakersfield, California, United States | Recruiting |
| California Cancer Associates for Research & Excellence ( Site 0016) | Fresno, California, United States | Completed |
| Providence Medical Foundation ( Site 0087) | Fullerton, California, United States | Completed |
| The Angeles Clinic and Research Institute ( Site 0005) | Los Angeles, California, United States | Active Not Recruiting |
| UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0009) | Los Angeles, California, United States | Recruiting |
| University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0076) | Orange, California, United States | Completed |
| Stanford Cancer Center ( Site 0086) | Palo Alto, California, United States | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0004) | San Francisco, California, United States | Recruiting |
| Providence Saint John's Health Center ( Site 0059) | Santa Monica, California, United States | Recruiting |
| University of Colorado Cancer Center ( Site 0021) | Aurora, Colorado, United States | Recruiting |
| Yale Cancer Center ( Site 0014) | New Haven, Connecticut, United States | Active Not Recruiting |
+ 768 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.